REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 26th, 2020 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 18, 2020 (the “Execution Date”), is entered into by and between Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”) and Cavalry Fund I LP, a Delaware limited partnership (the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in that certain Equity Line Purchase Agreement by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
EQUITY LINE PURCHASE AGREEMENTEquity Line Purchase Agreement • May 26th, 2020 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS EQUITY LINE PURCHASE AGREEMENT (the “Agreement”), is entered into as of May 18, 2020 (the “Execution Date”), by and between Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”), and Cavalry Fund I LP, a Delaware limited partnership (the “Investor”).
NOTE MODIFICATION AND FOREBAREANCE AGREEMENTNote Modification and Forbearance Agreement • May 26th, 2020 • Endonovo Therapeutics, Inc. • Pharmaceutical preparations • New York
Note Modification and Forbearance Agreement, dated as of May 20, 2020, by and among Endonovo Therapeutics, Inc., a Delaware corporation, with an address of 6320 Canoga Avenue - 15th Floor, Woodland Hills, CA 91367 (“ENDV”) and the party set forth on the signature page hereto (the “Lender”);
